Immuneering Corporation (IMRX)
- Previous Close
1.2900 - Open
1.3200 - Bid 1.2100 x 100
- Ask 1.2600 x 100
- Day's Range
1.2101 - 1.3200 - 52 Week Range
1.0000 - 3.8300 - Volume
188,518 - Avg. Volume
203,979 - Market Cap (intraday)
44.622M - Beta (5Y Monthly) -0.26
- PE Ratio (TTM)
-- - EPS (TTM)
-2.0400 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
11.10
Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 that is in Phase 1/2a clinical trial for the treatment of patients with solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.
immuneering.comRecent News: IMRX
View MorePerformance Overview: IMRX
Trailing total returns as of 5/2/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: IMRX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: IMRX
View MoreValuation Measures
Market Cap
44.62M
Enterprise Value
12.64M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
1.08
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-51.57%
Return on Equity (ttm)
-92.51%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-61.04M
Diluted EPS (ttm)
-2.0400
Balance Sheet and Cash Flow
Total Cash (mrq)
36.14M
Total Debt/Equity (mrq)
10.06%
Levered Free Cash Flow (ttm)
-33.65M